Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 24Colorectal Neoplasms 16Small Cell Lung Carcinoma 6Stomach Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Rectal Neoplasms 3Osteosarcoma 3Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1

Interventions

Filgrastim 13Peripheral Blood Stem Cell Transplantation 10Melphalan 9Ifosfamide 9Etoposide 9Cyclophosphamide 8Thiotepa 6Carboplatin 6Busulfan 6Radiotherapy 5Doxorubicin 5Vincristine 3Topotecan 3Temozolomide 3Docetaxel 3trioctyl phosphine oxide 2temsirolimus 2etoposide phosphate 2Transplantation 2Surgical Procedures, Operative 2Stem Cell Transplantation 2Radiotherapy, Intensity-Modulated 2Microarray Analysis 2Mesna 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Dexrazoxane 2Cisplatin 2Bone Marrow Transplantation 2Amifostine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroectodermal Tumors, Primitive, Peripheral × irinotecan sucrosofate × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡